HLOSF (Healios KK) Interest Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HLOSF Healios KK HLOSF
56 GF Score
Price $1.80
GF Value $0.33
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Healios KK Interest Received?

Interest Received only applicable to companies reporting Cash Flow from Operations in direct method.

HLOSF
56GF Score
Healios KK HLOSF
Interest Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Healios KK (HLOSF) Overvalued in 2026?

Based on GuruFocus' analysis, Healios KK stock appears to be overvalued. The current stock price of $1.80 is trading 445.5% above its estimated GF Value™ of $0.33. GuruFocus considers Healios KK to be Significantly Overvalued.

Key valuation signals for HLOSF:

  • Interest Received:
  • GF Value™: $0.33 vs. price of $1.80 (445.5% above fair value)
  • GF Score™: 56/100 with 5 warning signs

No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Healios KK Business Description

Other Exchanges 4593:Japan6VX:Germany
Address 1-1-2 Yurakucho, Hibiya Mitsui Tower 12Floor, Work Styling, Chiyoda-ku, Tokyo, JPN, 100-0006
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
56GF Score

Get the complete analysis for HLOSF

Interest Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.80
Price
$0.33
GF Value